Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q1 2021 Earnings Presentation
32 slides from Orion Oyj Class A's earnings presentation, Apr 27, 2021
Slide 1: Orion Result Presentation 1-3/2021
Orion Result Presentation 1−3/2021
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-March 2021
Highlights in January-March 2021
Slide 4: Strong start for the year with exceptional circumstances continuing
Strong start for the year with exceptional circumstances continuing Net sales & • Additional demand caused by the COVID-19 pandemic had a material operating profit improving impact on net sales and operating profit in the comparison period. • Due to the pandemic, demand of certain products is still
Slide 5: Key figures 1-3/2021
Key figures 1−3/2021 Net sales Operating profit Operating profit Cash flow per share margin before financial items 269 75 28% 0.19 MEUR (280) MEUR (84) (30%) EUR (0.34) -4% -11% -43% Result presentation 1-3/2021 © Orion Corporation 27 April 2021 5
Slide 6: Development of net sales in 1-3/2021 vs. 1-3/2020
Development of net sales in 1-3/2021 vs. 1-3/2020 280 -9 4 -4 -5 -2 -1 3 3 269 * Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing **** Without Nubeqa® royalties Result presentation 1-3/2021 © Orion Corporation 27 Apr
Slide 7: Development of operating profit in 1-3/2021 vs. 1-3/2020
Development of operating profit in 1-3/2021 vs. 1-3/2020 84 -8 -16 12 75 2 3 -2 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effect Resu
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-3/2021 MEUR 1-3/2021 1-3/2020 14% 120 28% +8% 10% 100 -12% 94 80 84 87 74 -28% 60 +7% 40 51 +18% 13% 37 38 36 35% 20 26 22 Finland Scandinavia 0 Other Europe North America RoW RoW = Rest of the World Result presentation 1-3/2021 © Orion Corporati
Slide 9: Net sales were at a good level but declined from strong comparison period
Net sales were at a good level but declined from strong comparison period 1−3/2021 1−3/2020 1-3/2021 MEUR -8 % 8% 160 -7% 135 7% 140 124 120 104 111 39% 100 80 +42% -17% 60 46% 40 23 21 19 15 20 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion and Animal Health Products
Slide 10: TOP 10 products in 1-3/2021
TOP 10 products in 1-3/2021 EUR million vs. 1-3/2020 1. Stalevo®, Comtess®, Comtan® 29 +4% 2. Easyhaler® product portfolio 26 -25% 3. Simdax® 15 -25% 4. dexdor® 12 -27% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 10 +8% 6. Nubeqa® 8 +102% 7. Solomet® 6 +43% 8. Divina® series 6 -2% 9. Burana® 5
Slide 11: Proprietary Products
Proprietary Products 6 RION ing well-being Buildi
Slide 12: Pandemic has a strong impact on demand for Easyhaler products
Pandemic has a strong impact on demand for Easyhaler® products Proprietary Products MEUR -25% sales split 1-3/2021 40 +4% 35 13% 35 29 28 8% 28% 30 26 -25% -27% +57% 25 19 20 17 15 +102% 14 15 12 9 14% 10 8 4 5 12% 25% 0 Easyhaler® Parkinson's Simdax® Dexdor® Nubeqa® Others portfolio franchise Parki
Slide 13: Easyhaler product portfolio sales -25%
Easyhaler® product portfolio sales -25% 1-3/2021 Budesonide-formoterol Easyhaler® MEUR 16 (20) -21% 40 1-3/2021 Other Easyhaler® products MEUR 10 (14) -31% 35 30 Sales, MEUR 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 Other Budesonide-formoter
Slide 14: Parkinson's franchise sales +4%
Parkinson’s franchise sales +4% 1-3/2021 Own sales MEUR 14 (13) +4% 40 35 1-3/2021 Deliveries to partners MEUR 16 (15) +4% 30 Sales, MEUR 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 Orion own sales Deliveries to partners Result presentation 1-
Slide 15: Dexdor and Simdax - impact of generic competition starting to show
Dexdor® and Simdax® - impact of generic competition starting to show 1-3/2021 Dexdor® MEUR 12 (17) -27% 1-3/2021 Simdax® MEUR 15 (19) -25% 20 20 15 15 10 10 5 5 0 0 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Result presentation 1-3/2021 © Orion Corporation 27 April 2021 15
Slide 16: Specialty Products
Specialty Products
Slide 17: Good quarter for Specialty Products even though net sales declined from strong Q1 2020
Good quarter for Specialty Products even though net sales declined from strong Q1 2020 -12% MEUR Sales split 1−3/2021 80 74 70 65 14% 60 50 -26% +3% +23% 18% 40 30 26 19 22 21 52% 17 20 14 10 0 16% Finland Scandinavia Eastern RoW Europe & Finland Russia Scandinavia Eastern Europe & Russia 1-3/2021 1
Slide 18: Good quarter for Specialty Products even though net sales declined from strong Q1 2020
Good quarter for Specialty Products even though net sales declined from strong Q1 2020 MEUR Sales split 1−3/2021 -7% 120 99 100 92 25% 80 -13% 60 36 40 31 20 0 75% Generic Self Care products prescription drugs Generic drugs Self-care products 1-3/2021 1−3/2020 Result presentation 1-3/2021 © Orion Co
Slide 19: In Finland, Orion's reference priced prescription drugs developed better than the market
In Finland, Orion’s reference priced prescription drugs developed better than the market The market for reference priced prescription drugs in Finland* The sales of Orion's reference (1−3/2021) priced prescription drugs in Finland MEUR 101(113) MEUR 25 (27) Market development Orion’s development -10
Slide 20: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−3/2021 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 698 million prescription Orion market share in MEUR drugs pharmacy 80 75 Orion market share in 70 25 pharmacy
Slide 21: Research and development
Research and development
Slide 22: Key clinical development pipeline
Key clinical development pipeline Phase completed Phase ongoing Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate
Slide 23: Key business targets in 2021
Key business targets in 2021 STATUS on TARGET 31 Mar 2021 Supporting sales growth and co-promotion in Europe with Bayer Positive outcome from Phase III ARASENS trial Taking phase III ARANOTE trial forward together with Bayer Sales growth ODM-208 Taking the development program forward according to pl
Slide 24: Orion committed to achieving carbon neutrality in its own operations by 2030
Orion committed to achieving carbon neutrality in its own operations by 2030 – steps towards the target Identifying climate impacts Reducing emissions Compensation Consistent reporting (scope 1 & 2) since 2009 Systematic steps towards the target The remaining carbon (Scope 1 & 2) footprint necessary
Slide 25: Outlook
Outlook GRION Building well-being
Slide 26: Outlook for 2021
Outlook for 2021 Net sales Orion estimates that in 2021 net sales will be slightly lower than in 2020 (net sales in 2020 were EUR 1,078 million). Operating profit Operating profit is estimated to be lower or clearly lower than in 2020 (in 2020 operating profit was EUR 280 million). Result presentati
Slide 27: Key assumptions behind the outlook
Key assumptions behind the outlook Net sales Operating profit + Nubeqa® + Nubeqa® + Other growing products + No more depreciation expenses from Parkinson’s franchise - Milestones - Milestones - dexdor® - dexdor® - Simdax® - Simdax® - Animal Health - Normalisation of cost level (without Parkinson’s d
Slide 28: Upcoming events
Upcoming events Capital Markets Day 2021 26/5/2021 Half-Year Financial Report 19/7/2021 Interim Report 1-9/2021 20/10/2021
Slide 29: Building well-being
Building well-being GRIoN Building well-being
Slide 30: Appendix
Appendix GRIoN Building well-being
Slide 31: Net sales and operating profit by quarter
Net sales and operating profit by quarter Net sales Operating profit 350 120 300 100 250 80 200 60 150 40 100 50 20 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Result presentation 1-3/2021 © Orion Corporation 27 April 2021 31
Slide 32: Quarterly net sales by unit (MEUR)
Quarterly net sales by unit (MEUR) Proprietary Products Specialty Products 150 150 100 100 50 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Animal Health Fermion & Contract Manufacturing 30 30 20 20 10 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 2017 20